业务
货币单位:EUR
2024/Q2
名称营收比例
Research and development of T cell redirecting immunotherapies for the treatment of cancer1,875.5万100.00%
地区
货币单位:EUR
2023/FY
名称营收比例
BMS, United States5,069.5万93.88%
Moderna, United States536.9万9.94%
Genmab, Denmark-206.7万-3.83%